OP0248 Inhibition of Sclerostin with Romosozumab in Postmenopausal Women with Low Bone Mineral Density: Phase 2 Trial Results
Michael R. McClung(Bone Health and Osteoporosis Foundation), Henry G. Bone(University of Arizona), José Zanchetta(Universidad del Salvador), Jean‐Yves Reginster(King Saud University), Jacques P. Brown(Centre hospitalier de l'Université Laval), Judy Maddox(Amgen (United States)), Leonid Katz(Amgen (United States)), Adolfo Díez‐Pérez(Tufts University), Steven Boonen(KU Leuven), Bente Langdahl(Aarhus University Hospital), Andreas Grauer(Omeros Corporation (United States)), Yang Yu(Nanjing Drum Tower Hospital), Cesar Libanati(Amgen (United States))
Cited by 5
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k